# EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

> **NCT02234843** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 500 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT02234843
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-13
- **Primary completion:** 2019-01-30
- **Final completion:** 2019-01-30
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2020-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02234843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02234843, "EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02234843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*